Aurobindo to acquire Lannett Company for Rs. 2,185 Cr
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The inspection was conducted from July 22-25, 2025
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Subscribe To Our Newsletter & Stay Updated